SUMMIT, N.J., August 25, 2026
Vascarta Inc. outlined new and previously generated preclinical and clinical evidence supporting the potential of its lead candidate VAS-101 (Vasceptor®) as a non-opioid approach to pain management across sickle cell disease (SCD), chemotherapy-induced pain and osteoarthritis (OA). The clinical-stage pharmaceutical company is developing VAS-101 as a transdermal curcumin formulation using its proprietary Vasporta™ delivery platform. The company’s latest update focuses on evidence suggesting that different pain conditions may converge on inflammatory signaling involving IL-17A, TNF-α and p38 MAPK, providing a potential common therapeutic pathway for VAS-101.
VAS-101 Targets Shared Inflammatory Pain Signaling
Vascarta’s development strategy centers on the potential of VAS-101 to address inflammatory and neuro-inflammatory mechanisms associated with pain, rather than relying on opioid-mediated pain suppression. According to the company, studies across different disease models have identified IL-17-driven p38 MAPK signaling in neuronal and glial cells as a potentially important contributor to pain sensitization. In sickle cell disease models, transdermal curcumin reduced mechanical and cold hypersensitivity while also decreasing markers associated with inflammation, mast-cell activation, neuronal injury and hemolysis. Additional mechanistic work indicated that VAS-101 suppressed spinal IL-17A–TNF-α/p38 MAPK signaling following hypoxia/reoxygenation and reduced microglial activation and hyperalgesia. These findings form a key part of Vascarta’s rationale for investigating VAS-101 across multiple pain settings.
Preclinical Data Extend VAS-101 Potential Beyond Sickle Cell Disease
Vascarta is also evaluating whether the same biological pathway can be targeted in chemotherapy-induced peripheral pain and osteoarthritis. In a breast cancer mouse model, VAS-101 reduced mechanical, cold and musculoskeletal hyperalgesia associated with cisplatin treatment while maintaining the chemotherapy’s antitumor activity. The company reported reductions in spinal IL-17A and cisplatin-associated p38 MAPK activation, together with evidence of neuronal and mitochondrial protection. In osteoarthritis, the program has already generated Phase 1b clinical evidence: in a randomized, double-blind, placebo-controlled study in adults with knee OA, VAS-101 produced a statistically significant reduction in KOOS pain scores and daily pain ratings versus placebo, while approximately 40% of participants reported meaningful improvement within 28 days. Complementary preclinical studies also suggest potential effects on microvascular perfusion and tissue oxygenation during simulated vaso-occlusion, adding another area of investigation for the platform.
Advertisement
Transdermal Platform Supports Vascarta’s Development Strategy
A central element of Vascarta’s approach is the Vasporta™ gel-based transdermal delivery platform, designed to facilitate delivery of curcumin through the skin and into circulation. The company is seeking to overcome the poor oral bioavailability of curcumin, which has historically limited its clinical utility. VAS-101 is exclusively licensed to Vascarta from the Albert Einstein College of Medicine and is being developed as a potential systemic treatment delivered through a transdermal formulation. Vascarta believes the platform could allow a single therapeutic approach to address inflammatory pathways shared by SCD pain, chemotherapy-induced pain and OA, potentially reducing reliance on opioid-based treatments. The company said it plans to advance IND submissions while continuing development with its collaborators. However, the evidence remains a combination of preclinical findings and early-stage clinical data, meaning the broader efficacy claims across multiple indications still require confirmation in adequately powered later-stage clinical trials.
Source:Vascarta, press relese
